Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

AI can accurately measure hair loss severity in alopecia areata.

This study found that the Alopecia Areata Symptom Impact Scale (AASIS) is a better tool than the Alopecia Areata Quality of Life Index (AA-QLI) for assessing patient-reported outcomes in alopecia areata.

This article presents a dissenting opinion, arguing that the case described by Dr. Molina et al. was diffuse alopecia areata, not acute alopecia areata as claimed, emphasizing the importance of distinct clinical differences.

This study identified a new genetic locus, ahl4, on distal Chromosome 10 that contributes to the early-onset, severe hearing loss in A/J mice compared to B6 mice.

In a mouse model study, researchers found that mutations in Aire reduced alopecia areata frequency, while Notch4 mutations did not lead to the disease, likely due to proximity with a resistance gene.

This study found that targeting both hormonal and immune pathways improved treatment outcomes in androgenetic alopecia patients with an under-recognized inflammatory component called PIILIF, which may contribute to treatment resistance.

In this report, a unique female presentation of IFAP syndrome is described, featuring musculoskeletal contractures but no photophobia, highlighting the importance of early detection and multidisciplinary care to improve outcomes and prevent disability.

This study identified multiple factors affecting the severity of alopecia areata, suggesting they could inform a tool for measuring disease impact and guide treatment selection.

This article reviews alopecia areata incognita, a rare condition mostly seen in young women, and discusses its similarities and differences with telogen effluvium; however, it reports no new clinical findings.

This study found that Aminexil clinical 5 significantly reduced hair loss in men and women with mild alopecia and was well tolerated with high subject satisfaction.

This report presents a case of IFAP syndrome with the typical symptoms of alopecia universalis, severe photophobia, and follicular ichthyosis, but provides no additional clinical findings or conclusions.

This paper presents consensus guidelines for standardized diagnostic criteria and assessment methods for frontal fibrosing alopecia to improve clinical research and data collection globally.

This study found that ATR-FTIR spectroscopy combined with machine learning effectively differentiated alopecia areata patients from healthy controls with an AUC of 0.85, and also showed promise in predicting treatment response, particularly through alterations in the Amide I band.

This study found that vibration assisted analgesia reduced pain during intralesional corticosteroid therapy for hair loss, enabling treatment in a broader range of patients, including those with needle phobia.

This review covers the current status of the interstitial pneumonia with autoimmune features (IPAF) category, pointing out the need for revision of its criteria to establish it as a standalone diagnostic term, but reports no new clinical findings.

In this case report, a 3-year-old male with IFAP syndrome showed moderate improvement in skin symptoms and corneal erosions but no change in alopecia or photophobia after 6 months of acitretin therapy.

This study found that a 3D wound model, the 3DWoundSE, showed improved responsiveness to injury and cytotoxic stimuli compared to an intact 3D skin equivalent, offering a reproducible and ethical alternative to animal models for early wound response assessment in dermatological research and drug development.

This study reports that trichoscopy and histopathology can effectively diagnose alopecia areata incognito and differentiate it from telogen effluvium or androgenetic alopecia, aiding clinicians in better hair regrowth management.

In this study, intralesional triamcinolone acetonide injections were associated with halting the progression of frontal fibrosing alopecia in female patients and showed minimal adverse effects, but the efficacy as sole therapy remains unclear pending further trials.

This case report describes a 6-year-old girl with IFAP syndrome who showed good improvement in cutaneous symptoms after one month of acitretin treatment.

This study evaluated 129 patients with androgenetic alopecia and identified an inflammatory pattern of perifollicular infiltration linked to treatment resistance. Targeting both hormonal and immune pathways improved outcomes for 67% of patients, suggesting inflammation may play a role in some cases of stubborn hair loss.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

This study found that intramuscular anti-IFN-γ significantly stabilized and promoted hair regrowth in alopecia areata patients with patchy, progressive hair loss, whereas those with total baldness showed more limited improvement.

In this study, freezing gamma-irradiated amniotic fluid increased hair follicles and accelerated the transition to the anagen stage in rats, suggesting potential for treating hair loss safely and effectively.

This study reported that a novel ionic liquid delivery system combining ferulic acid and finasteride enhanced the solubility, skin permeation, and effectiveness in promoting hair regrowth in androgenetic alopecia mice, suggesting an improved topical treatment approach.

This study introduces ALUDWIG, an automated tool for assessing female androgenic alopecia severity from smartphone images, which may offer a more consistent alternative to current scoring methods like the Ludwig scale.

This study found a severe MBTPS2 gene mutation in a Japanese IFAP syndrome patient, suggesting other factors may influence the syndrome's clinical features compared to previously studied patients.

This study found that serum MIF levels were significantly higher in patients with extensive alopecia areata compared to those with mild alopecia areata and healthy individuals.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

This report describes a case of alopecia areata incognita in a 6-year-old child, marked by sudden diffuse hair loss without bald patches, typically observed in adults.